Major histocompatibility complex class II-proinsulin peptide complex (MHCII-proinsulin complex)

The Major histocompatibility complex (MHC) class II-proinsulin peptide complex is a pivotal molecular structure in the development of Type 1 diabetes mellitus (T1D). It consists of a specific HLA molecule, most commonly HLA-DQ8 or HLA-DR4, which binds proinsulin-derived peptides within its peptide-binding groove (Noble & Erlich, 2012, PubMed). This complex is then recognized by the T-cell receptor (TCR) of autoreactive CD4+ T cells, initiating an immune response against pancreatic beta cells (Peakman, 2013, Clinical & Experimental Immunology). Because this interaction is a primary driver of islet autoimmunity, it serves as a high-priority target for antigen-specific immunotherapies. Therapeutic approaches include the use of small molecules like methyldopa, which occupies the HLA-DQ8 groove to prevent proinsulin peptide binding (Michels et al., 2018, JCI Insight). Other strategies involve peptide-based vaccines, such as the C19-A3 peptide, designed to induce regulatory T cells and restore immune tolerance to proinsulin (Alhadj Ali et al., 2017, Science Translational Medicine). By targeting this specific pMHC-TCR interface, clinicians aim to preserve remaining beta-cell function in newly diagnosed patients. This approach offers a more precise alternative to broad immunosuppression, potentially reducing side effects while addressing the underlying cause of the disease.

Other names

HLA-DQ8-proinsulin complexHLA-DR4-proinsulin complexpMHC complexProinsulin-MHC II complex

Competitive inhibition of peptide binding to the MHC groove, induction of immune tolerance, or blockade of T-cell receptor recognition.